Upgraded version of immunotherapy: hopefully cure cancer completely

Company Profile

Immunovative Therapies is an Israeli clinical stage biopharmaceutical company focused on developing technologies and products for cancer and infectious disease immunotherapy. The company uses the workings of the immune system to protect people from disease and turn it into products that harness the power of the immune system to treat cancer and infectious diseases.

The company is headquartered in Jerusalem, Israel, and was established in 2004. It is independent from the Hadassah Hebrew University Medical Center and is financially supported by the Israel Office of the Chief Scientist. . Currently, the company operates mainly in Israel, Phoenix, Arizona, and Bangkok, Thailand.

Core technologies and products

Immunovative Therapies' technology platform "Mirror Effect" is based on the immune mechanisms that have been shown to eliminate chemotherapy-resistant metastatic tumors and HIV.

The clinical application of immune mechanisms is limited and it is fatal. The innovation of the "mirror effect" platform is that it can maintain the efficacy of the immune mechanism and eliminate toxicity.

The "mirror effect" technique enhances the effect of allograft surgery by reversing the flow direction of immunity. The transplanted immune system directly affects the immune effects of GVT and GVHD. The "mirror" in the "mirror effect" or the direction of reversing the immune effect is closely related to the host and has little to do with the transplanted tissue. In this manner, the host's immune system rejection promotes the host immune system to attack tumor cells. The related HVT/HVG effect is a mirror of the allogeneic gene hematopoietic stem cell transplant tumor/GVH effect.

Infusion of the same cells for cancer patients does not produce any anti-tumor effects. Clinical studies have shown that the sequence that affects anti-tumor is as follows: Graft-host or host-grafts can occur in any direction.

First, establish a stable chimeric immune system: a mixed immune system, a mixture of a donor's immune transplant system and a cancer patient's immune system. To create a chimeric immune system, it is necessary to start with the first chemotherapy conditioning, inhibit the autoimmune system, and accept the transplantation of allogeneic tissue. After chemotherapy, allogeneic immune cells can be transplanted into part of the body and can be regenerated.

With chimeric conditions, more donor immune cells are infused into the host and begin to reject the remaining host immune cells. The rejection of host immune cells is a powerful auxiliary support to support the GVT effect. However, when the GVT effect occurs, the donor's immune system kills normal cells, resulting in graft versus host disease.

The company found that the above process can be reversed or "mirrored". Under chimeric conditions, host immune cell infusion results in immune system rejection of the transplant donor. This host anti-graft rejection (HVG) graft is resistant to host "mirror" (GVH) effects. At the same time, the "mirror" host anti-graft (HVG) rejection is not toxic, as a result of the lethal toxicity associated with host rejection. HVG rejection acts as a helper host anti-tumor effect (HVT), as a GVT effect of allogeneic transplantation, and is closely related to avirulent HVG rejection. In a chimeric setup, the GVT effect occurs in normal cell transplantation disease (GVHD). The HVT effect occurs in host rejection grafts. Unlike GVHD, HVG rejection is not toxic.

The human immune system has been rejecting outsiders before. Before the discovery of immune effects, most researchers believe that the GVT effect of allogeneic transplantation occurs because the transplanted immune system is necessary to fight tumors. It is impossible to observe this phenomenon in the mirror of HVT. When the HVT effect occurs, both the tumor and the immune cells are from the same person.

However, they are wrong. A chimeric immune system can observe the effect of non-toxic HVT on the specular effect. The chimeric immune system requires the patient to first undergo chemotherapy, not to kill the tumor, but to suppress the immune system so that it does not reject the donor immune system. To further reduce the chances of the host immune system rejecting the transplanted immune system, tissue matching is required. Matching organizations are best seen from several siblings.

Through the mechanism of action of HVT, scientists at Immunovative Therapies have introduced a design that can reverse the HVT mechanism into donor transplantation, called "AlloStim." The patented immune cell transplant is derived from immune cells of a healthy donor who deliberately mismatches. AlloStim can cause HVT in normal patients, eliminating the need for conditioning and tissue matching.

Immunovative Therapies has developed a product that combines the response of the patient with the specular effects of the immune system response. By developing immune tool products and integrating products into controllable steps, an unprecedented immune system control is achieved. This control can be achieved even in severe preconditioning, high tumor burden, metastatic cancer patients or patients with incurable infectious diseases such as AIDS, hepatitis, herpes, Ebola, malaria, etc. By providing the corresponding products at different stages of the disease and having a corresponding strategic plan, the company can train the immune system to distinguish cancer cells or virus-infected cells, produce an effective immune response and label cancer cells that have not been eliminated or Viruses, tissue cancer cells and viruses evade immune attacks.

leading a team

Michael Har-Noy

Dr. Michael Har-Noy is the founder of the Immunopative Therapies and the inventor of the "mirror effect" technology. He has worked in academia and business for many years, overcoming difficulties and trying to harness the power of the immune system to treat cancer and AIDS.

One night, Dr. Har-Noy, when analyzing all the failed immunological data, made a whimsy and created a “mirror effect” to treat cancer and AIDS. It is very difficult to do this because in the early 2000s, the entire academic community was not optimistic about the use of immunotherapy to treat cancer.

Dr. Har-Noy overcame numerous obstacles and established the Immunological Therapies to develop products based on mirror effect technology. The company has recruited a team of professionals to conduct manufacturing, monitoring and clinical trials.

Butyl Rubber Stopper For Film Coated

We are a chinese origin manufacturer , we majored in producing rubber products for almost 10 years , which allows us to offer a wide range products for you . Our products now are widely used in clinical injection, transfusion and other packaging. We now have a 100-100000 class cleaning workshop which meets the GMP standard. From input to output, we have a strict quality control throughout the whole production line. We have full test instruments and tools according to the standard documents.

Butyl Rubber Stopper For Film Coated,Stopper For Film Coated,Silicone Rubber Stopper,Butyl Bottles Silicone Rubber Stopper

SUZHOU CRH PHARMACEUTICAL TECHNOLOGY CO.,LTD , https://www.crh-health.com